Peter Grogg
Directeur/Membre du Conseil chez BACHEM HOLDING AG
Fortune : 3 782 M $ au 30/04/2024
Provenance du réseau au premier degré de Peter Grogg
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 | |
| Public Company | Chemicals: Specialty | 7 | |
Kenta Biotech AG
 Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland.
7
| Private Company | Biotechnology | 7 |
Bachem AG
 Bachem AG Pharmaceuticals: MajorHealth Technology Bachem AG engages in the sale and distribution of active pharmaceutical ingredients and research grade products. The firm’s products include peptides and complex organic molecules, as well as new chemical entities and generic active pharmaceutical ingredients. It also focuses on peptide research and development, including custom peptide synthesis. The company was founded by Peter Grogg in 1971 and is headquartered in Bubendorf, Switzerland.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Ingro Finanz AG
 Ingro Finanz AG Financial ConglomeratesFinance Ingro Finanz AG provides investment services. The company is based in Bubendorf, Switzerland.
1
| Subsidiary | Financial Conglomerates | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Peter Grogg via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| UBS | Investment Managers | Corporate Officer/Principal | |
| ACINO HOLDING AG | Pharmaceuticals: Major | Director of Finance/CFO | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Operating Officer | |
Sunstar-Holding AG
 Sunstar-Holding AG Hotels/Resorts/Cruise linesConsumer Services Sunstar-Holding AG engages in the operation of holiday hotels. The company was founded by Fritz Buser and Ernst Rieder on March 14, 1969 and is headquartered in Liestal, Switzerland. | Hotels/Resorts/Cruise lines | Chairman Director/Board Member | |
Rentschler Arzneimittel GmbH
 Rentschler Arzneimittel GmbH Pharmaceuticals: MajorHealth Technology Part of MEDICE Arzneimittel Pütter GmbH & Co. KG, Rentschler Arzneimittel GmbH is a German company that manufactures over-the-counter drugs. The company is based in Laupheim, Germany. Rentschler Arzneimittel was acquired by MEDICE Arzneimittel Pütter GmbH & Co. KG from Dr. Rentschler Holding GmbH & Co. KG on March 16, 2006. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
Schering GmbH & Co. Produktions KG
 Schering GmbH & Co. Produktions KG Pharmaceuticals: MajorHealth Technology Schering GmbH & Co. Produktions KG manufactures medicines for treating disorders of the menstrual cycle. The company's product Primolut N contains norethisterone which is a progestogen (a female hormone) used to treat irregular, painful or heavy periods. It is also used in the treatment of endometriosis (presence of tissue from the lining of the womb in places where it is not normally found). Schering GmbH was founded in 1851 and is headquartered in Weimar, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Nextech Invest AG
 Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Investment Managers | Chief Executive Officer | |
| University of California, Irvine | College/University | Doctorate Degree | |
| University of California, Santa Barbara | College/University | Chief Tech/Sci/R&D Officer | |
| Technische Universität München | College/University | Doctorate Degree | |
MDS Pharma Services (Canada)
 MDS Pharma Services (Canada) Miscellaneous Commercial ServicesCommercial Services MDS Pharma Services provides contract drug discovery and drug development services for pharmaceutical and biotechnology companies. It provides its clients with early-stage, clinical research and late-stage drug discovery and development services, such as Phase I-IV testing, target discovery and lead optimization. The company is located in Saint-Laurent, Canada. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Karlsruhe | College/University | Doctorate Degree | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Graduate Degree | |
| University of Basel | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Bayreuth | College/University | Undergraduate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Chief Administrative Officer Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Rentschler Biopharma SE
 Rentschler Biopharma SE Pharmaceuticals: MajorHealth Technology Rentschler Biopharma SE develops and produces pharmaceutical products. Its solutions include bioprocess development, bio manufacturing, associated consulting activities including cell line process, cell culture, aseptic filling, consulting, planning and project management services. The company was founded in 1927 and is headquartered in Laupheim, Germany. | Pharmaceuticals: Major | Chairman | |
Dr. Rentschler Holding GmbH & Co. KG
 Dr. Rentschler Holding GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services Dr. Rentschler Holding GmbH & Co. KG operates as a holding company with interests in pharmaceutical research and production. Its services include project management, cell line and process developing, as well as analytics and quality controlling solutions. The company was founded in 1927 and is headquartered in Laupheim, Germany. | Miscellaneous Commercial Services | Chief Executive Officer | |
| University of Bern | College/University | Doctorate Degree Doctorate Degree | |
| Evolma Holding AG | Director/Board Member | ||
Systag System Technik AG
 Systag System Technik AG Medical SpecialtiesHealth Technology Systag System Technik AG specializes in laboratory automation. The private company is based in Ruschlikon, Switzerland. The Swiss company has been a leading partner for chemical and pharmaceutical production facilities worldwide since 1965. The CEO of the company is Marcel Haugg. | Medical Specialties | Director/Board Member | |
| SPEXIS AG | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
| Liverpool John Moores University | College/University | Undergraduate Degree | |
PricewaterhouseCoopers AG (Zurich)
 PricewaterhouseCoopers AG (Zurich) Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers AG provides assurance, tax and advisory services. The company is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor | |
| Bachem Bioscience, Inc. | Chief Operating Officer President | ||
The Genetics Co., Inc.
 The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Medical/Nursing Services | Chairman Director/Board Member | |
SV Group AG
 SV Group AG RestaurantsConsumer Services SV Group AG engages in the hotel management and restaurant trade. It focuses on the community catering, hospital and home catering, event catering, public restaurant, and hotel industries. The company was founded by Else Züblin-Spiller in 1914 and is headquartered in Dübendorf, Switzerland. | Restaurants | Director/Board Member | |
Bachem Americas, Inc.
 Bachem Americas, Inc. Pharmaceuticals: MajorHealth Technology Bachem Americas, Inc. engages in development of pharmaceutical ingredients through solid-phase peptide synthesis. The company is headquartered in Torrance, CA. | Pharmaceuticals: Major | Chairman Chairman President | |
Dottikon Exclusive Synthesis AG
 Dottikon Exclusive Synthesis AG Pharmaceuticals: MajorHealth Technology Dottikon Exclusive Synthesis AG manufactures pharmaceutical ingredients. Its products and services exclusive synthesis, project management, performance chemicals, containment, quality management, recycling and waste treatment, and dottisol. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
Solvias AG
 Solvias AG BiotechnologyHealth Technology Solvias AG engages in contract research, development, and manufacturing. It offers analytical, small molecule, biopharmaceutical, solid state development, catalysis technology, custom synthesis and manufacturing, and biological analysis services. The firm serves the pharmaceutical, biotech, medical devices, cosmetics, agro chemical, chemical, eletronic materials, and life sciences industries. The company was founded in 1999 and is headquartered in Kaiseraugst, Switzerland. | Biotechnology | Director of Finance/CFO | |
| Migros Verteilzentrum Suhr AG | Comptroller/Controller/Auditor | ||
Basel Chamber of Commerce
 Basel Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services The Basel Chamber of Commerce is an organization that advocates for the interests of the industry and promotes the region as the most important logistics hub in Switzerland. The non-profit company is based in Basel, Switzerland. The company also has a Swiss School for International Business. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Bachem (U.K.) Ltd.
 Bachem (U.K.) Ltd. Pharmaceuticals: MajorHealth Technology Part of Bachem Holding AG, Bachem (U.K.) Ltd. is a leading, British innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company is based in St. Helens, UK. The company's dedicated and experienced project leaders ensure the development and manufacturing of products through close collaboration with the project team. Whatever the needs for non-GMP products, Bachem can prepare compounds according to specifications in any scale. Founded in 1986, the company provides solutions for today and innovation for tomorrow. | Pharmaceuticals: Major | Chairman Director/Board Member Corporate Officer/Principal | |
| MFC Beteiligungs AG | Chairman Director/Board Member | ||
| Dottikon Es Management AG | Director/Board Member Director/Board Member Corporate Officer/Principal | ||
| Dottikon Es America, Inc. | Director/Board Member Chief Executive Officer | ||
| Aerzte Treuhand G Deragisch | Comptroller/Controller/Auditor | ||
Targimmune Therapeutics AG
 Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
Rentschler Immobilien GmbH & Co. KG
 Rentschler Immobilien GmbH & Co. KG Financial ConglomeratesFinance Rentschler Immobilien GmbH & Co. KG provides investment services. The private company is based in Laupheim, Germany. The CEO of the German company is Nikolaus Friedrich Rentschler. | Financial Conglomerates | Chief Executive Officer | |
Rentschler Biotechnologie Beteiligungs GmbH
 Rentschler Biotechnologie Beteiligungs GmbH Financial ConglomeratesFinance Part of Dr. Rentschler Holding GmbH & Co. KG, Rentschler Biotechnologie Beteiligungs GmbH is a German company that provides investment services. The company is based in Laupheim, Germany. The CEOs of the company are Jürgen Müller, Nikolaus Friedrich Rentschler. | Financial Conglomerates | Chief Executive Officer | |
| Zhaw School of Engineering | College/University | Undergraduate Degree | |
Rentschler Beteiligungs GmbH
 Rentschler Beteiligungs GmbH Financial ConglomeratesFinance Rentschler Beteiligungs GmbH is an investment holding German company. The private company is based in Laupheim, Germany. The CEOs are Nikolaus Friedrich Rentschler, Jürgen Müller. The company was founded in 1998. | Financial Conglomerates | Chief Executive Officer | |
Vaderis Therapeutics AG
 Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Biotechnology | Chief Operating Officer | |
| POLYPEPTIDE GROUP AG | Biotechnology | Sales & Marketing |
Statistiques
Internationale
| Suisse | 29 |
| Allemagne | 14 |
| Etats-Unis | 6 |
| Royaume-Uni | 3 |
| Canada | 2 |
Sectorielle
| Health Technology | 18 |
| Consumer Services | 15 |
| Finance | 6 |
| Commercial Services | 6 |
| Health Services | 2 |
Opérationnelle
| Director/Board Member | 54 |
| Corporate Officer/Principal | 43 |
| Chairman | 24 |
| Chief Executive Officer | 16 |
| Doctorate Degree | 15 |
Relations les plus connectées
- Bourse
- Insiders
- Peter Grogg
- Connexions Sociétés
